Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due ot issues of adverse effects is a second-line agent reserved for those who do not respond ot other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe isease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line uagents however due to issues of adverse effects is a second-line uagent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due to ifssues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however vdue to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effcts is a second-line agent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the reclapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse cffeets is a second-line agent reserved for those who do not respond to other treatments or with severe disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with svere disease
Natalizumab reduces the relapse rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease|Natalizumab reduces the relase rate more than first-line agents however due to issues of adverse effects is a second-line agent reserved for those who do not respond to other treatments or with severe disease
